Bevacizumab induces ferroptosis and enhances CD8⁺ T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9.

已完结 20 由花九卿发布于 2025/7/25 21:15:33

DOI:10.1038/s41401-024-01299-4
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1038/s41401-024-01299-4

其它数据库

Abstract：Bevacizumab is a recombinant humanized monoclonal immunoglobulin (Ig) G1 antibody of VEGF, and inhibits angiogenesis and tumor growth in hepatocellular carcinoma (HCC). Ferroptosis, a new fo

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:American Chemical Society (ACS)CaWRKY01-10 和 CaWRKY08-4 通过直接激活一组防御相关基因增强辣椒对荚膜真菌感染的抵抗力

Bevacizumab induces ferroptosis and enhances CD8+ T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9.

Bevacizumab induces ferroptosis and enhances CD8⁺ T cell immune activity in liver cancer via modulating HAT1 and increasing IL-9.